Trial reportBlood2012
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.
Trial report in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Comparative genomics analysis of mononuclear phagocyte subsets confirms homology between lymphoid tissue-resident and dermal XCR1(+) DCs in mouse and human and distinguishes them from Langerhans cells.Journal of immunological methods · 2016Pooled it
- Dendritic cells: the central partner for cancer immunity.Oncoimmunology · 2025Review
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Overview of dendritic cells subsets and their involvement in immune-related pathological disease.BioImpacts : BI · 2025Review
- Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DC.European journal of immunology · 2025Article
- mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Cross-presenting Langerhans cells are required for the early reactivation of resident CD8Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.Blood advances · 2022Article
- New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.International journal of molecular sciences · 2022Review
- Immunotherapy in Multiple Myeloma.Cells · 2020Review
- Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities.Frontiers in oncology · 2020Review
- Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses.Cancers · 2019Review
- IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.Blood advances · 2018Article
- 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.Blood advances · 2018Article
- Human dendritic cell subsets: an update.Immunology · 2018Review
- Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.Journal of leukocyte biology · 2017Review
- Dendritic Cell Therapies for Hematologic Malignancies.Molecular therapy. Methods & clinical development · 2017Review
- Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.Cancer immunology research · 2017Article
- Cellular and vaccine immunotherapy for multiple myeloma.Hematology. American Society of Hematology. Education Program · 2016Review
- Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
Human CD34(+) progenitor-derived Langerhans-type dendritic cells (LCs) are more potent stimulators of T-cell immunity against tumor and viral antigens in vitro than are monocyte-derived DCs (moDCs). The exact mechanisms have remained elusive until now, however. LCs synthesize the highest amounts of IL-15R-α mRNA and protein, which binds IL-15 for presentation to responder lymphocytes, thereby signaling the phosphorylation of signal transducer and activator of transcription 5 (pSTAT5). LCs electroporated with Wilms tumor 1 (WT1) mRNA achieve sufficiently sustained presentation of antigenic peptides, which together with IL-15R-α/IL-15, break tolerance against WT1 by stimulating robust autologous, WT1-specific cytolytic T-lymphocytes (CTLs). These CTLs develop from healthy persons after only 7 days' stimulation without exogenous cytokines and lyse MHC-restricted tumor targets, which include primary WT1(+) leukemic blasts. In contrast, moDCs require exogenous rhuIL-15 to phosphorylate STAT5 and attain stimulatory capacity comparable to LCs. LCs therefore provide a more potent costimulatory cytokine milieu for T-cell activation than do moDCs, thus accounting for their superior stimulation of MHC-restricted Ag-specific CTLs without need for exogenous cytokines. These data support the use of mRNA-electroporated LCs, or moDCs supplemented with exogenous rhuIL-15, as vaccines for cancer immunotherapy to break tolerance against self-differentiation antigens shared by tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.